A carregar...
Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
A subcutaneous formulation of trastuzumab to treat patients with HER2-positive breast cancer is available since August 2013. The subcutaneous formulation is administered as a fixed dose of 600 mg over a period of up to 5 minutes. The HannaH trial compared subcutaneous with intravenous administration...
Na minha lista:
| Publicado no: | Geburtshilfe Frauenheilkd |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Georg Thieme Verlag KG
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490923/ https://ncbi.nlm.nih.gov/pubmed/26166837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0035-1546172 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|